Financial Contrast: Bionano Genomics (NASDAQ:BNGO) and Stevanato Group (NYSE:STVN)
by Michael Walen · The Markets DailyStevanato Group (NYSE:STVN – Get Free Report) and Bionano Genomics (NASDAQ:BNGO – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
Insider and Institutional Ownership
11.3% of Bionano Genomics shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Stevanato Group and Bionano Genomics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stevanato Group | $1.34 billion | 4.53 | $158.21 million | €0.56 | 35.81 |
| Bionano Genomics | $28.51 million | 0.60 | -$26.40 million | ($3.02) | -0.48 |
Stevanato Group has higher revenue and earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Stevanato Group and Bionano Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stevanato Group | 10.99% | 10.43% | 6.16% |
| Bionano Genomics | -106.58% | -78.78% | -48.54% |
Analyst Ratings
This is a breakdown of current recommendations for Stevanato Group and Bionano Genomics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stevanato Group | 0 | 3 | 2 | 2 | 2.86 |
| Bionano Genomics | 1 | 0 | 1 | 0 | 2.00 |
Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 315.22%. Given Bionano Genomics’ higher probable upside, analysts plainly believe Bionano Genomics is more favorable than Stevanato Group.
Volatility & Risk
Stevanato Group has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.
Summary
Stevanato Group beats Bionano Genomics on 11 of the 15 factors compared between the two stocks.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
About Bionano Genomics
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.